Kristie McNealy, MD

Tomorrow, we’ll be getting back to our regularly scheduled programming. We appreciate everyone’s patience with the recent problems with the site, including outages, and pages loading extremely slowly. We’re 99.9% sure we’ve got the problem solved, so things should be back to normal from here on out.

In the meantime, here’s a little roundup of recent women’s health breakthroughs in the news:

• Advaxis CSO, Dr. John Rothman presented clinical trial data on their groundbreaking live Listeria vaccine for cervical cancer treatment, Lovaxin C, at the American Associate for Cancer Research. We filled you in on the original trial results here in February.
• Also from the American Association for Cancer Research meeting, a new vaccine against HER2-positive breast cancer cells may reduce deaths by 50%. The vaccine has been licensed to Apthera under the brand name NeuVax.
• A new test is in the works that identifies breast cancer tumors that are likely to produce a large number of circulating cancer cells, making them more likely to metastasize. This will allow targeted therapy to women with higher risk tumors.
• For our readers in the UK, next week is also Cervical Cancer Screening Awareness Week.

Similar Posts:

• Vaccine to Treat Cervical Cancer is Safe
• Breast Cancer Treatment found by Studying Downs Syndrome
• Early Detection is Key in Breast Cancer Survival
• 3 Benefits of Breastfeeding